Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Short term Debt (2022 - 2023)

Historic Short term Debt for C4 Therapeutics (CCCC) over the last 2 years, with Q2 2023 value amounting to $10.3 million.

  • C4 Therapeutics' Short term Debt rose 127800.0% to $10.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.3 million, marking a year-over-year increase of 127800.0%. This contributed to the annual value of $2.3 million for FY2022, which is N/A changed from last year.
  • C4 Therapeutics' Short term Debt amounted to $10.3 million in Q2 2023, which was up 127800.0% from $2.3 million recorded in Q1 2023.
  • In the past 5 years, C4 Therapeutics' Short term Debt ranged from a high of $10.3 million in Q2 2023 and a low of $750000.0 during Q1 2022